Hims & Hers Health is a top growth stock with strong cash flow, no debt, and an innovative AI-powered platform. Learn more on ...

The latest trend in treating hair loss may sound familiar — essentially, it’s a repurposed drug first popularized in the 1990s. Back then, TV viewers were inundated with ...

Hims & Hers Health ( HIMS 7.49%) stock slid 7.4% through 11:10 a.m. ET Tuesday after Bank of America raised its price target ...

Millich, a former U.S. Army sergeant, hadn’t suspected his Hims finasteride prescription was at fault ... select a drug they ...

Hims & Hers is shutting down the dermatology business it acquired four years ago, Business Insider has learned. On Friday, the telehealth company discontinued Apostrophe, the direct-to-consumer ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...

March 7 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being ...

Shares of Hims & Hers Health (HIMS) tumbled 15% yesterday after Novo Nordisk (NVO) announced it was cutting the price of its GLP-1 weight-loss drug Wegovy by more than half. The move obliterates ...

Hims & Hers Health (NYSE: HIMS) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some (vicariously) bad news out of the Great State of Texas. The U.S. District Court for ...

Telehealth company Hims & Hers Health (HIMS ... semaglutide on its platform after the first quarter, triggering mixed reviews from analysts about the future of its weight loss business.

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading ...